JP2002511868A5 - - Google Patents

Download PDF

Info

Publication number
JP2002511868A5
JP2002511868A5 JP1999505580A JP50558099A JP2002511868A5 JP 2002511868 A5 JP2002511868 A5 JP 2002511868A5 JP 1999505580 A JP1999505580 A JP 1999505580A JP 50558099 A JP50558099 A JP 50558099A JP 2002511868 A5 JP2002511868 A5 JP 2002511868A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1999505580A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002511868A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/012414 external-priority patent/WO1999000129A1/en
Publication of JP2002511868A publication Critical patent/JP2002511868A/ja
Publication of JP2002511868A5 publication Critical patent/JP2002511868A5/ja
Ceased legal-status Critical Current

Links

JP50558099A 1997-06-30 1998-06-15 増殖性硝子体網膜症を治療するためのカルシウム遮断薬 Ceased JP2002511868A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5196297P 1997-06-30 1997-06-30
US60/051,962 1997-06-30
PCT/US1998/012414 WO1999000129A1 (en) 1997-06-30 1998-06-15 Calcium blockers to treat proliferative vitreoretinopathy

Publications (2)

Publication Number Publication Date
JP2002511868A JP2002511868A (ja) 2002-04-16
JP2002511868A5 true JP2002511868A5 (https=) 2005-12-22

Family

ID=21974492

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50558099A Ceased JP2002511868A (ja) 1997-06-30 1998-06-15 増殖性硝子体網膜症を治療するためのカルシウム遮断薬

Country Status (6)

Country Link
US (4) US6380261B1 (https=)
EP (1) EP0994709A4 (https=)
JP (1) JP2002511868A (https=)
AU (1) AU727080B2 (https=)
CA (1) CA2295098A1 (https=)
WO (1) WO1999000129A1 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU727080B2 (en) * 1997-06-30 2000-11-30 Allergan, Inc. Calcium blockers to treat proliferative vitreoretinopathy
US20050009884A1 (en) * 1997-06-30 2005-01-13 Dreyer Evan B. Calcium blockers to treat proliferative retinal diseases
US6291506B1 (en) 1998-08-04 2001-09-18 Wisconsin Alumni Research Foundation Method of reducing retinal ganglion cell degeneration
JP2002528416A (ja) * 1998-10-27 2002-09-03 アルコン ラボラトリーズ， インコーポレーテッド 外網膜の疾患の治療
NZ513111A (en) * 1998-12-24 2003-10-31 R Tech Ueno Ltd Agent for treating visual cell function disorder
US6864232B1 (en) 1998-12-24 2005-03-08 Sucampo Ag Agent for treating visual cell function disorder
JP2002182418A (ja) * 2000-12-11 2002-06-26 Konica Corp 画像形成方法、画像形成装置
FR2822706A1 (fr) * 2001-03-29 2002-10-04 Univ Pasteur Utilisation de composes organiques antagonistes de recepteurs pour le traitement de la degenerescence retinienne
US8557855B2 (en) * 2002-07-03 2013-10-15 Allergan, Inc. Methods of using ryanodine antagonists in treating neural injury
US20050031652A1 (en) * 2003-02-25 2005-02-10 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
US20050147584A1 (en) * 2004-01-05 2005-07-07 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050277698A1 (en) * 2004-01-05 2005-12-15 Hughes Patrick M Memantine delivery to the back of the eye
DE602005011928D1 (de) 2004-01-20 2009-02-05 Allergan Inc Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon-acetonid und hyaluronsäure
EP1737452A1 (en) * 2004-04-06 2007-01-03 Angiogenetics Sweden AB Angiogenesis-affecting compounds and methods of use thereof
WO2006033020A2 (en) * 2004-04-26 2006-03-30 Rosetta Genomics Ltd. Methods and apparatus for the detection and validation of micrornas
US7122128B2 (en) * 2004-04-29 2006-10-17 General Electric Company Phosphors containing borate of terbium, alkaline-earth, and Group-3 metals, and light sources incorporating the same
US20050244478A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Anti-excititoxic sustained release intraocular implants and related methods
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US20050244462A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Devices and methods for treating a mammalian eye
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US8591885B2 (en) * 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20050244458A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
WO2005107708A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Biodegradable intravitreal tyrosine kinase inhibitors implants
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
US8455656B2 (en) 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
WO2006017347A2 (en) * 2004-07-12 2006-02-16 Allergan, Inc. Opthalmic compositions and methods for treating ophthalmic conditions
BRPI0513862A (pt) * 2004-07-26 2008-05-20 Allergan Inc métodos de tratar condições oftálmicas
WO2006043965A1 (en) * 2004-10-14 2006-04-27 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20070167527A1 (en) * 2006-01-13 2007-07-19 Burke James A Memantine for the normalization of visual acuity deficits
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US7911053B2 (en) * 2007-04-19 2011-03-22 Marvell World Trade Ltd. Semiconductor packaging with internal wiring bus
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
DK2498783T3 (en) 2009-11-09 2018-12-10 Allergan Inc COMPOSITIONS AND PROCEDURES FOR STIMULATING HAIR GROWTH
EP2956096A1 (en) 2013-02-15 2015-12-23 Allergan, Inc. Sustained drug delivery implant
AU2015243537B2 (en) 2014-04-08 2020-10-22 The Methodist Hospital INOS-inhibitory compositions and their use as breast cancer therapeutics

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) * 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US4755388A (en) * 1984-11-09 1988-07-05 The Regents Of The University Of California Liposome-encapsulated 5-fluoropyrimidines and methods for their use
CA2004616A1 (en) * 1988-12-05 1990-06-05 Craig E. Crosson Therapeutic use of calcium entry blockers in retinal or optic nerve dysfunction
ZA906583B (en) * 1989-08-21 1991-09-25 Beth Israel Hospital Method and composition for the treatment of cutaneous,ocular,and mucosal hypersensitivity,inflammatory,and hyperproliferative conditions using topical preparations of nifedipine
US5521215A (en) * 1989-11-07 1996-05-28 Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-blocking pharmaceuticals
US5356902A (en) * 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5922773A (en) * 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5602156A (en) * 1993-09-17 1997-02-11 The United States Of America As Represented By The Department Of Health And Human Services Method for inhibiting metalloproteinase expression
US5424321A (en) * 1993-12-08 1995-06-13 Alcon Laboratories, Inc. Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents
US6013628A (en) * 1994-02-28 2000-01-11 Regents Of The University Of Minnesota Method for treating conditions of the eye using polypeptides
FR2717080B1 (fr) * 1994-03-09 1996-12-13 Synthelabo Utilisation de l'éliprodil et de ses énantiomères pour la préparation de médicaments utiles dans le traitement des neuropathies périphériques et des maladies neurodégénératives centrales.
US5516522A (en) * 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US5597809A (en) * 1994-06-23 1997-01-28 Massachusetts Eye & Ear Infirmary Treatment of optic neuritis
US5710165A (en) * 1994-07-06 1998-01-20 Synthelabo Use of polyamine antagonists for the treatment of glaucoma
US5431907A (en) * 1994-08-03 1995-07-11 Abelson; Mark B. Treatment of vascular disorders of the posterior segment of the eye by topical administration of calcium channel blocking agents
US5623051A (en) * 1994-11-10 1997-04-22 University Of Washington Methods and compositions for screening for presynaptic calcium channel blockers
US5604244A (en) * 1995-06-07 1997-02-18 Alcon Laboratories, Inc. Intraocular irrigating solution containing a polyamine antagonist
FR2738568B1 (fr) 1995-09-08 1997-10-17 Synthelabo Derives de 4-(cycloalkyl)piperidines et 4-(cycloalkylalkyl) piperidines, leur preparation et leur application en therapeutique
FR2738567B1 (fr) 1995-09-08 1997-10-17 Synthelabo Derives de alpha-phenylpiperidine-1-propanol, leur preparation et leur application en therapeutique
SI0848707T1 (en) 1995-09-08 2000-02-29 Sanofi-Synthelabo 4-(cycloalkyl)piperidines and 4-(cycloalkylalkyl)-piperidines derivatives, preparation thereof and therapeutical applications thereof
AU727080B2 (en) * 1997-06-30 2000-11-30 Allergan, Inc. Calcium blockers to treat proliferative vitreoretinopathy
JP2002528416A (ja) * 1998-10-27 2002-09-03 アルコン ラボラトリーズ， インコーポレーテッド 外網膜の疾患の治療
US6482854B1 (en) * 1999-03-25 2002-11-19 Massachusetts Eye And Ear Infirmary Glaucoma treatment

Similar Documents

Publication Publication Date Title
JP2000509942A5 (https=)
JP2000510751A5 (https=)
JP2000507042A5 (https=)
JP2000509912A5 (https=)
JP2000509635A5 (https=)
JP2000509637A5 (https=)
JP2000509587A5 (https=)
JP2000507369A5 (https=)
JP2000507433A5 (https=)
JP2002511084A5 (https=)
JP2000508866A5 (https=)
JP2000510793A5 (https=)
JP2000508022A5 (https=)
JP2000508841A5 (https=)
JP2000508680A5 (https=)
JP2000509804A5 (https=)
JP2000509853A5 (https=)
JP2000509755A5 (https=)
JP2000510247A5 (https=)
JP2000510969A5 (https=)
JP2000508102A5 (https=)
JP2000508836A5 (https=)
JP2000509818A5 (https=)
JP2000509520A5 (https=)
JP2000507434A5 (https=)